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Abstract
Objective Conventional risk factors for coronary artery
disease fail to explain the increased frequency or cardio-
vascular morbidity in systemic lupus erythematosus (SLE)
patients. This study was conducted to determine the
possible influence of autoimmune and inflammatory phe-
nomena markers on coronary artery calcifications and
myocardial perfusion abnormalities in SLE patients.
Materials and methods Multi-detector computed tomog-
raphy (MDCT)-based coronary calcium scoring and single
photon emission computerized tomography (SPECT)
studies (Tc-99m sestamibi) were performed in 60 SLE
patients in stable clinical condition, without a prior history
of coronary artery disease. Laboratory evaluation included
serum C-reactive protein (CRP), complement C3c and C4
components and antiphospholipid antibodies (aPL). The latter
included anticardiolipin (aCL) and anti-b2-glycoprotein I
(ab2GPI) antibodies, of both IgG and IgM classes, and
lupus anticoagulant (LA) in plasma.
Results SPECT revealed persistent perfusion defects in
22 (36.7%) patients and exercise-induced defects in eight
(13.3%), while MDCT revealed coronary calcifications in
15 (25%). Calcium scores ranged from 1 to 843.2 (mean
113.5 ± 259.7). No association was found between con-
ventional coronary artery disease risk factors (obesity,
hypertension, tobacco use, hyperlipidaemia, diabetes) nor
CRP, C3c or C4 levels and coronary calcifications or
myocardial perfusion defects. On the contrary, in patients
with these pathologies, augmented autoimmunization was
found, reflected by increased aCL IgG and antib2GPI IgG
levels. In patients with aCL IgG [20 RU/ml or antib2GPI
IgG [3 RU/ml, the relative risk of coronary calcification
formation was 4.1 compared to patients with normal val-
ues. Accordingly, in LA-positive patients the relative risk
of coronary calcification formation was 4.4 compared to
LA-negative patients.
Conclusions Conventional risk factors for coronary artery
disease as well as markers of an ongoing inflammation did
not show any association with perfusion defects and/or
coronary artery calcifications in SLE patients. On the
contrary, calcified atherosclerotic plaques and myocardial
perfusion defects were observed mainly in patients with
elevated levels of anticardiolipin and ab2GPI antibodies
of the IgG class. It might be speculated that coronary
artery calcifications and perfusion defects are a result
of antiphospholipid antibodies-induced coronary artery
microthrombosis.
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Systemic lupus erythematosus (SLE) is a generalized
autoimmune disease, in which a diffuse, chronic inflam-
matory reaction plays an important etiological role.
Nowadays, the mortality of SLE patients is influenced by
increased occurrence of severe cardiovascular complica-
tions [1].
Conventional risk factors for coronary artery disease
(diabetes, hypertension, tobacco use, hyperlipidaemia,
sedentary lifestyle) do not explain the increased risk of
atherosclerosis and cardiovascular complications in SLE
patients [2]. The other possible mechanisms include a
generalized, chronic inflammation, reflected by high
C-reactive protein (CRP) level. The relation between the
increased CRP level and life-threatening cardiovascular
episodes is well documented [2]. The other characteristic
finding in generalized inflammation is a reduced level of
complement system components (mainly C3c and C4).
Beside the chronic inflammation, the second factor that
may potentially influence pathologic changes in the arteries
is the presence of antiphospholipid antibodies (aPL). Ele-
vated aPL levels are related to an increased risk of
thrombosis in the arteries and microcirculation [3–7]. The
coexistence of aPL and thrombosis in the above-mentioned
vascular beds meets the criteria for the diagnosis of anti-
phospholipid syndrome [8], which appears in one-third of
SLE patients [9].
Aim of the study
This study was conducted to determine the influence of
chronic inflammation and the presence of aPL on coronary
artery calcifications and myocardial perfusion abnormali-
ties in SLE patients assessed by multi-detector computed
tomography (MDCT)-based coronary calcium scoring and
single photon emission computed tomography (SPECT).
Methods
Inclusion and exclusion criteria
The study was performed in 60 consecutive patients treated
for systemic SLE in the Department of Internal Medicine,
Jagiellonian University Medical College, Krakow, Poland.
All patients fulfilled at least four American College of
Rheumatology classification criteria for SLE [10, 11].
Before the study, informed consent was obtained from each
patient. The study protocol conforms to the ethical guide-
lines of the 1975 Declaration of Helsinki. The study was
approved by the Ethical Committee of the Jagiellonian
University in Krakow.
Inclusion criteria comprised stable clinical conditions of
SLE (no need for immunosuppressive therapy intensifica-
tion, i.e. current immunosuppressive drug dose increase or
introduction of an additional immunosuppressive drug
within the last 3 months). Exclusion criteria were as fol-
lows: prior history of coronary artery disease, known
cancer, clinical symptoms of heart failure (NYHA III or IV
class), renal failure (creatinine clearance\30 ml/min) and/
or respiratory failure.
Patients studied
In the group of 60 patients examined, 54 (90%) were
females andsix(10%) males, aged 20–73 years (mean age
51.8 years). The duration of the disease at the time of
examination was between 2 and 32 years (mean
15.5 years). Three patients had been previously diagnosed
with antiphospholipid syndrome (APS) based on the
revised APS classification criteria [8]. One of the three
suffered from an objectively confirmed pulmonary embo-
lism. There were two tobacco smokers; none of the
patients was obese. The history revealed arterial hyper-
tension in three subjects; there were no diabetic patients.
ECG recordings at rest were normal in all the patients. The
results of peripheral blood count, serum sodium, potas-
sium, glucose, creatinine and urinalysis were all normal.
The distribution of the patients according to their SLEDAI
score [12] is shown in Table 1. The main complaints at
inclusion were arthralgias and, among laboratory findings,
low complement levels and increased ANA titers (see
below). The immunosuppressive treatment included
methylprednisolone in 32 (53.3%) subjects (B4 mg for
clinical stability maintenance), prednisone in two (3.3%),
chloroquine derivate in five (8.3%), azathioprine in four
(6.7%), cyclophosphamide in three (5%), and methotrex-
ate in two (3.3%). The remaining patients had not used
any immunosuppressive drugs in the last 12 months of
observation. Other treatment included angiotensin-con-
verting enzyme inhibitors in four (6.7%) subjects, beta-
blockers in three (5%) and calcium channel blockers in
two (3.3%). APS patients were treated with anticoagulant
(warfarin, two patients) or antiplatelet therapy (aspirin,
one patient).
The presence and types of autoantibodies identified in
the patients examined as well as the concentrations of CRP
and complement C3c and C4 components are shown in
Table 2.
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SPECT study
In all the patients SPECT studies (ECAM Gamma Camera,
Siemens, Germany) were performed at rest and during
exercise in a 2-day protocol. On the first day, at near
maximal stress, a 25–40 mCi dose of Tc-99m sestamibi
was injected (the actual dose was modified taking into
account the patient’s weight) and the exercise was con-
tinued forone additional minute after the injection. Tc-99m
sestamibi SPECT imaging was begun 15–30 min later. On
the second day, rest examinations were performed. SPECT
was performed using a circular 180 acquisition for 60
projections at 20 s per projection. Myocardial perfusion
was assessed in 17 left ventricle myocardial segments. The
number of segments with persistent or exercise-induced
perfusion defects were assessed visually by analysts blin-
ded to any other information.
Coronary calcium scoring
Coronary calcium scoring was performed using a multide-
tector CT imager (Somatom Definition, Siemens, Germany).
The images were ECG-triggered with 3-mm-thick sections
obtained covering the whole heart. Coronary artery calcifi-
cations were defined as lesions with attenuation greater than
130 HU in more than four adjacent pixels. In order to
quantify coronary calcium, 3D Leonardo application (Sie-
mens, Germany) was used. The number of atherosclerotic
plaques in particular coronary arteries and their volume were
assessed. The Agatson calcium score was calculated [13].
Laboratory tests
Standard laboratory tests were performed. Additionally, the
levels of CRP (high-sensitivity) and complement system
C3c and C4 factors were assessed by nephelometry (Siemens,
Germany).
Serum levels of anticardiolipin (aCL) and anti-b2-gly-
coprotein I (ab2GPI) antibodies (of both IgG and IgM
classes) were measured using a home-made ELISA with
Sapporo standard for antib2GPI antibody measurements
(HCAL for IgG, EY2C9 for IgM) [9]. The values
exceeding the 99th percentile of a healthy population
sample were considered positive.
Lupus anticoagulant (LA) determination was performed
in accordance with the three-step procedure recommended
by the International Society on Thrombosis and Haemo-
stasis [14].
Statistical analysis
Statistical analysis was performed using Statistica Six
Sigma software. All numerical data were expressed as
mean values ± standard deviations or as proportions.
Continuous variables were compared using the t test. The
chi-square test was used to examine differences in pro-
portions. The level for statistical significance was
predetermined at p \ 0.05. To adjust for the confounding
Table 1 SLEDAI score in SLE patients at the time of study











Table 2 Autoantibodies and other laboratory parameters measured in SLE patients studied
Range (mean ± SD) Number of patients with
out-of-range levels (%)
aCL IgG [RU/ml] 0.68–121.56 (14.4 ± 20.3) 20 (33.3)
aCL IgM [RU/ml] 1.62–52.93 (12.1 ± 10.6) 26 (43.3)
antib2GPI IgG [RU/ml] 0.16–95.33 (3.8 ± 15.3) 8 (13.3)
antib2GPI IgM [RU/ml] 0.14–21.66 (2.2 ± 3.7) 24 (40)
LA – 11 (18.3)
ANA [titer] 0–1/20,480 56 (93.3)
CRP [mg/l] 0.18–41.70 (4.16 ± 7.40) 11 (18.3)
C3c [g/l] 0.43–1.39 (0.90 ± 0.25) 32 (53.3)
C4 [g/l] 0.02–0.26 (0.13 ± 0.05) 16 (26.7)
aCL Anticardiolipin antibodies (cut-off value for IgG [20 RU/ml, for IgM [30 RU/ml; see ‘‘Methods’’), antib2GPI antib2-glycoprotein I
antibodies (cut-off value for IgG [3 RU/ml, for IgM [2.6 RU/ml; see ‘‘Methods’’), LA lupus anticoagulant, ANA antinuclear antibodies, CRP
C-reactive protein. Elevated value for CRP [5 mg/l. Decreased values for C3c \0.9 g/l, for C4 \0.1 g/l
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effect of age on SPECT and MDCT results, an ANOVA
model was used with age as a covariate.
Results
In 37 (61.6%) out of 60 patients examined, pathologic
results of SPECT or MDCT studies were found. Figure 1
shows examples of coronary calcifications and myocardial
perfusion defect observed in a patient with elevated aPL
levels.
SPECT study revealed myocardial perfusion abnormal-
ities in 30 (50.0%) patients: persistent defects in 22
(36.7%) patients, exercise-induced defects in 8 (13.3%).
The distribution of patients according to the number of
underperfused myocardial segments of the left ventricle is
shown in Table 3. Out of 30 patients with perfusion
abnormalities, in 21 (70% of this group) classic signs of
ischaemia (horizontal or down-slope ST depression
C0.1 mV) were visible in ECG recordings during exercise.
MDCT revealed coronary calcifications in 15 (25%)
patients. The number of atherosclerotic calcified plaques
ranged from 1 to 23 (mean 6 ± 6.9), their volume 2–761.8
(108.8 ± 234.2) mm3. Calcium scores ranged from 1 to
843.2 (mean 113.5 ± 259.7).
The distribution of patients according to perfusion
abnormalities and coronary calcifications in particular
coronary arteries is shown in Table 4.
Myocardial perfusion abnormalities together with the
presence of coronary calcifications were present in nine
(15%) patients. In 21 (35%) patients SPECT study was
abnormal despite the lack of coronary calcifications (cal-
cium score = 0). On the other hand, in six (10%) patients
with mild calcium deposits [1–3 plaques, calcium score
4.4–35.1 (mean 14.87 ± 14.24)], SPECT study did not
show perfusion defects.
We found no influence of conventional risk factors for
coronary artery disease (obesity, hypertension, tobacco use,
hyperlipidaemia, diabetes) on coronary calcifications for-
mation or myocardial perfusion defects (Tables 5, 6). The
generalized inflammation reflected by high CRP and low
C3c and C4 levels did not significantly result in the pres-
ence of atherosclerotic lesions or perfusion disturbances.
Fig. 1 Examples of MDCT (above) and SPECT (below) results in a
patient with elevated aCL IgG (26.11 RU/ml), elevated antib2GPI
IgG (3.66 RU/ml) and positive lupus anticoagulant test
Table 3 The distribution of SLE patients according to the number of
myocardial segments with perfusion abnormalities in SPECT study






0 38 (63.3) 52 (86.7)
1 – 2 (3.3)
2 7 (11.7) –
3 13 (21.7) 4 (6.7)
4 – 2 (3.3)
5 2 (3.3) –
Total 60 (100) 60 (100)
Table 4 The distribution of SLE patients according to perfusion
abnormalities and coronary calcifications in particular coronary
arteries
Coronary arteries SPECT (%) MDCT (%)
LAD 22 (73.3) 8 (53.3)
RCA 3 (10.0) 2 (13.3)
LAD ? RCA 3 (10.0) 1 (6.7)
LAD ? Cx 2 (6.7) –
LAD ? Cx ? RCA – 4 (26.7)
Total 30 (100) 15 (100)
LAD Left anterior descending artery, RCA right coronary artery, Cx
circumflex artery
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On the contrary, regardless of their age, in patients with
atherosclerotic plaques in coronary vessels or with myo-
cardial perfusion defects, augmented autoimmunization
was found, reflected as increased aCL IgG and antib2GPI
IgG levels (Tables 5, 6). Additionally, in patients with
coronary calcifications a significantly higher level of anti-
nuclear antibodies and higher frequency of lupus
anticoagulant incidence were observed (Table 5).
In all three patients with APS, perfusion defects were
observed on SPECT study, and in two of them coronary
atherosclerotic plaques were present.
In patients with elevated levels of aCL IgG [20 RU/ml
or antib2GPI IgG [3 RU/ml, the relative risk of coro-
nary calcification formation was 4.1 compared to patients
with normal values. Accordingly, in patients positive
for lupus anticoagulant, the relative risk of coronary
calcification formation was 4.4 compared to LA-negative
patients.
Discussion
The major findings of this study include the association of
coronary calcification formation and myocardial perfusion
abnormalities in SLE patients with the presence of anti-
phospholipid antibodies. Neither conventional coronary
artery disease risk factors (obesity, hypertension, tobacco
use, hyperlipidaemia, diabetes) nor CRP, C3c and C4




score = 0) and with coronary
calcifications on MDCT study






ns not significant. Values in
bold type are statistically
significant
Calcium score = 0 (n = 45) Calcium score [0 (n = 15) p
Age (years) 36.06 – 11.61 48.55 – 11.56 <0.01
Total cholesterol (mmol/l) 4.93 ± 1.10 5.0 ± 1.42 ns
LDL cholesterol (mmol/l) 2.51 ± 0.51 3.10 ± 1.38 ns
HDL cholesterol (mmol/l) 1.23 ± 0.18 1.38 ± 0.45 ns
Triglycerides (mmol/l) 1.54 ± 0.06 1.56 ± 0.74 ns
Glucose (mmol/l) 4.73 ± 0.23 4.0 ± 0.63 ns
CRP (mg/l) 4.48 ± 8.43 3.23 ± 3.24 ns
C3c (g/l) 0.89 ± 0.23 0.92 ± 0.30 ns
C4 (g/l) 0.14 ± 0.05 0.11 ± 0.06 ns
aCL IgG (RU/ml) 11.2 – 10.10 24.70 – 15.91 <0.05
aCL IgM (RU/ml) 11.6 ± 11.30 13.50 ± 9.00 ns
antib2GPI IgG (RU/ml) 1.31 – 1.18 11.61 – 10.91 <0.05
antib2GPI IgM (RU/ml) 2.13 ± 4.10 2.21 ± 2.23 ns
LA (n, %) 3 (6.7%) 8 (53.3%) <0.01
ANA (titer) 4668 – 2717 8320 – 4521 <0.05




perfusion defects and with
perfusion defects on SPECT
study






ns not significant. Values in
bold type are statistically
significant
Normal perfusion (n = 30) Perfusion defects (n = 30) p
Age (years) 34.9 – 10.92 42.75 – 13.68 <0.05
Total cholesterol (mmol/l) 5.55 ± 2.05 4.7 ± 0.45 ns
LDL cholesterol (mmol/l) 2.86 ± 0.88 3.10 ± 1.57 ns
HDL cholesterol (mmol/l) 1.31 ± 0.51 1.38 ± 0.38 ns
Triglycerides (mmol/l) 1.54 ± 0.61 1.57 ± 0.79 ns
Glucose (mmol/l) 4.8 ± 0.28 4.3 ± 0.42 ns
CRP (mg/l) 5.71 ± 10.07 2.6 ± 2.48 ns
C3c (g/l) 0.91 ± 0.25 0.89 ± 0.26 ns
C4 (g/l) 0.12 ± 0.05 0.13 ± 0.06 ns
aCL IgG (RU/ml) 11.99 – 4.66 16.03 – 13.6 <0.05
aCL IgM (RU/ml) 13.11 ± 12.12 11.12 ± 9.12 ns
antib2GPI IgG (RU/ml) 1.31 – 0.43 6.19 – 6.82 <0.05
antib2GPI IgM (RU/ml) 2.12 ± 4.9 2.17 ± 2.02 ns
LA (n, %) 5 (16.7%) 6 (20.0%) ns
ANA (titer) 4204 ± 4716 6837 ± 7823 ns
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levels revealed a significant influence on these pathologies
in the studied population.
Our results support the data previously published
showing the high frequency of myocardial perfusion
defects in SLE patients [15, 16]. Perfusion defects were
present in 50% of cases, despite normal rest ECG record-
ings and lack of myocardial ischaemia clinical symptoms.
In most of our patients the number of left ventricle und-
erperfused segments was low (2–3). It has to be stressed,
however, that even small perfusion defects in SPECT
strongly affect the prognosis in non-SLE populations
[17, 18]. We showed a higher frequency of persistent
perfusion abnormalities compared to exercise-induced
defects. This might be partially explained by the fact that
antiphospholipid antibodies are associated with thrombotic
events in coronary microcirculation [19], which is dis-
cussed below. Thrombosis in microcirculation might lead
to the small persistent perfusion defects observed in our
study, whereas exercise-induced defects, usually observed
in coronary artery disease, are caused by the presence of
atherosclerotic plaques narrowing the epicardial arteries.
Besides the presence of myocardial perfusion abnor-
malities, 25% of our asymptomatic SLE patients
manifested atherosclerosis in coronary arteries. Coronary
vessels are most frequently affected by calcifications; in a
recently published study of 50 SLE patients [20], the fre-
quency of atherosclerotic plaques observed in MDCT was
highest in coronary arteries (42% of patients with calcifi-
cations), followed by carotid arteries (24% of patients with
calcifications). In accordance with our findings, a study of
157 SLE patients showed that in young subjects with the
mean age of 40, the frequency of coronary artery calcifi-
cations is 30–40% [21]. This percentage is relatively higher
than in the general population: in a study of 35,388 subjects
calcium scores [10 were observed in only 10% of cases,
and calcium scores [100 in 2% [22]. Coronary calcium
deposits provide independent prediction of short- and long-
term cardiac events [23–25]. Even in patients with normal
SPECT results, the increased coronary calcium score
identifies subjects at high long-term cardiac risk [23].
Interestingly, our study did not show an influence of
conventional risk factors of coronary artery disease
(obesity, hypertension, tobacco use, hyperlipidaemia, dia-
betes) on coronary calcification formation or myocardial
perfusion defects. Moreover, a generalized inflammation
reflected by higher CRP and lower C3c and C4 concen-
trations did not significantly result in the presence of
atherosclerotic lesions. This may be due to the lack of
subjects with severely augmented inflammatory process in
our study: in patients with CRP levels [20 mg/l its influ-
ence on cardiovascular damage was reported [2].
In patients with myocardial perfusion defects or
atherosclerotic plaques in coronary vessels, augmented
autoimmunization was found, reflected as an increased aCL
IgG and antib2GPI IgG levels. The evidence that anti-
phospholipid autoantibodies play a role in thrombosis is
persuasive [3]. Various studies have suggested that these
antibodies may cause thrombosis by activation of endo-
thelial cells or platelets or by inhibition of the protein C
activation pathway [4–7]. Although antiphospholipid anti-
bodies are associated with arterial and venous thrombosis,
the extent to which they influence other clinical manifes-
tations is either controversial or uncertain. The data from
the literature based on echocardiography suggest its rela-
tion to valvular pathology [26], but in other studies no such
relation has been found [27]. There are, however, reports
showing higher titers of aCL [28] and antib2GPI [29]
antibodies in patients with SLE or MCTD and pulmonary
hypertension. It is tempting to speculate that perfusion
abnormalities results from thrombi formed in the coronary
microcirculation leading to perfusion defects in small
regions of myocardium. Such defects, localized predomi-
nantly in the segments supplied by the left anterior
descending artery, were observed in our study.
The antiphospholipid antibodies may also initiate or
exacerbate the process of lipid deposition and plaque for-
mation [30]. Among antiphospholipid antibodies, a crucial
role in the pathogenesis of atherosclerosis is attributed to
aCL antibodies and antib2GPI antibodies [31, 32].
Increased levels of antinuclear antibodies in patients
with coronary calcifications were also shown in our study.
There is little data concerning atherogenesis enhancement
by these antibodies. One in-vitro study [33] showed that
immune complexes consisting of anti-dsDNA, DNA and
LDL augmented cholesterol accumulation in vascular
smooth muscle cells and demonstrated cytotoxic activity. It
was also reported that determination of antinuclear anti-
bodies may be helpful also in the evaluation of coronary
artery disease risk in subjects in whom no generalized
autoimmune disease has been diagnosed [34].
Based on the positive results of SPECT and MDCT
studies in a high proportion of stable SLE patients without
cardiac symptoms, the question of final cardiac diagnosis
arises. MDCT is characterized by very high specificity
(95–97%) and excellent negative predictive value
(93–99%) for stable coronary artery disease diagnosis [35].
The specificity of SPECT is estimated to be 70–75% [35].
Thus, an early stage of coronary artery disease may be
diagnosed in patients with atherosclerotic plaques detected
by MDCT in our study, as well as in patients with positive
SPECT results, reflecting rather a ‘‘small vessel’’ type of
the disease.
Our results discussed above may have valuable impli-
cations for the management of SLE patients in the future.
The presence of atherosclerotic plaques and myocardial
perfusion defects on SPECT study are strong predictors of
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death [17, 18, 23–25]. The mechanism of formation of
these abnormalities, in which microthrombosis might play
a major role, should direct our attention to thrombosis
prevention in aPL-positive patients. It was reported that in
asymptomatic aCL-positive patients thrombo-prophylaxis
with aspirin or low-molecular-weight heparin during high-
risk periods (surgery, immobilization) is effective in
reducing thrombotic complications [36]. Among asymp-
tomatic aCL-positive SLE patients, primary prophylaxis
with aspirin and hydroxychloroquine also reduced the
frequency of thrombotic events [37]. The value of anti-
thrombotic treatment on perfusion abnormalities and
formation of coronary calcifications and, consequently, on
the prognosis of aCL-positive SLE patients should be
addressed in large prospective clinical trials. It should be
emphasized that the value of statin treatment in SLE
patients free from clinical symptoms of cardiovascular
disease has become an objective of ongoing randomized
studies [38].
Conclusion
Coronary calcified plaques and myocardial perfusion
defects are present in a high proportion of stable SLE
patients without cardiac symptoms. Conventional risk fac-
tors for coronary artery disease as well as markers of an
ongoing inflammation do not show an association with
these pathologies. On the contrary, atherosclerosis is aug-
mented in patients with increased levels of antiphospholipid
antibodies of IgG class. It might be speculated that coronary
artery calcifications and perfusion defects are a result of
coronary artery microthrombosis induced by antiphospho-
lipid antibodies.
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